Berberine inhibits prostate cancer progression by inducing ferroptosis: evidence from network pharmacology.

IF 1.8 4区医学 Q3 ONCOLOGY

Anti-Cancer Drugs Pub Date : 2025-01-14 DOI:10.1097/CAD.0000000000001691

Peiliang Zou, Shenghai Li, Qixiong He, Chixing Zheng

{"title":"Berberine inhibits prostate cancer progression by inducing ferroptosis: evidence from network pharmacology.","authors":"Peiliang Zou, Shenghai Li, Qixiong He, Chixing Zheng","doi":"10.1097/CAD.0000000000001691","DOIUrl":null,"url":null,"abstract":"<p><p>The uncertain ferroptosis-related role of berberine in prostate cancer was explored using network pharmacology methodology. Integration of ferroptosis targets in prostate cancer from the Genecard database and berberine targets from the Traditional Chinese Medicine Systems Pharmacology and SwissTargetPrediction databases revealed 17 common targets. Among these, 10 hub genes, including CCNB1, CDK1, AURKA, AR, CDC42, ICAM1, TYMS, NTRK1, PTGS2, and SCD, were identified. Enrichment analyses yielded 799 Gene Ontology terms and 23 Kyoto Encyclopedia of Genes and Genomes pathways associated with berberine-related targets. Molecular docking simulations indicated berberine's binding capacity to all hub genes. In-vitro studies on LNCaP and PC3 cells demonstrated berberine's inhibition of cell proliferation and significant downregulation of TYMS, CCNB1, AURKA, CDK1, and SCD in both cell lines. Berberine exhibited cell line-specific effects by reducing AR expression in LNCaP cells and suppressing ICAM1 in PC3 cells. Overall, berberine shows promise in inhibiting prostate cancer progression through modulation of ferroptosis-related genes, including TYMS, AR, CCNB1, AURKA, CDK1, ICAM1, NTRK1, SCD, and CDC42.</p>","PeriodicalId":7969,"journal":{"name":"Anti-Cancer Drugs","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anti-Cancer Drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/CAD.0000000000001691","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The uncertain ferroptosis-related role of berberine in prostate cancer was explored using network pharmacology methodology. Integration of ferroptosis targets in prostate cancer from the Genecard database and berberine targets from the Traditional Chinese Medicine Systems Pharmacology and SwissTargetPrediction databases revealed 17 common targets. Among these, 10 hub genes, including CCNB1, CDK1, AURKA, AR, CDC42, ICAM1, TYMS, NTRK1, PTGS2, and SCD, were identified. Enrichment analyses yielded 799 Gene Ontology terms and 23 Kyoto Encyclopedia of Genes and Genomes pathways associated with berberine-related targets. Molecular docking simulations indicated berberine's binding capacity to all hub genes. In-vitro studies on LNCaP and PC3 cells demonstrated berberine's inhibition of cell proliferation and significant downregulation of TYMS, CCNB1, AURKA, CDK1, and SCD in both cell lines. Berberine exhibited cell line-specific effects by reducing AR expression in LNCaP cells and suppressing ICAM1 in PC3 cells. Overall, berberine shows promise in inhibiting prostate cancer progression through modulation of ferroptosis-related genes, including TYMS, AR, CCNB1, AURKA, CDK1, ICAM1, NTRK1, SCD, and CDC42.

查看原文本刊更多论文

小檗碱通过诱导铁下垂抑制前列腺癌进展：来自网络药理学的证据。

利用网络药理学方法探讨了小檗碱在前列腺癌中与铁中毒相关的不确定作用。整合来自Genecard数据库的前列腺癌铁下垂靶点和来自中医系统药理学和SwissTargetPrediction数据库的小檗碱靶点，发现了17个共同靶点。其中，共鉴定出CCNB1、CDK1、AURKA、AR、CDC42、ICAM1、TYMS、NTRK1、PTGS2、SCD等10个枢纽基因。富集分析得到799个基因本体术语和23个与小檗碱相关靶点相关的京都基因和基因组百科全书路径。分子对接模拟显示了小檗碱与所有枢纽基因的结合能力。对LNCaP和PC3细胞的体外研究表明，小檗碱对两种细胞系的细胞增殖均有抑制作用，并显著下调TYMS、CCNB1、AURKA、CDK1和SCD。小檗碱通过降低LNCaP细胞中的AR表达和抑制PC3细胞中的ICAM1表现出细胞系特异性作用。总的来说，小檗碱通过调节铁致凋亡相关基因，包括TYMS、AR、CCNB1、AURKA、CDK1、ICAM1、NTRK1、SCD和CDC42，显示出抑制前列腺癌进展的希望。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Anti-Cancer Drugs 医学-药学

CiteScore

3.80

自引率

0.00%

发文量

244

审稿时长

3 months

期刊介绍： Anti-Cancer Drugs reports both clinical and experimental results related to anti-cancer drugs, and welcomes contributions on anti-cancer drug design, drug delivery, pharmacology, hormonal and biological modalities and chemotherapy evaluation. An internationally refereed journal devoted to the fast publication of innovative investigations on therapeutic agents against cancer, Anti-Cancer Drugs aims to stimulate and report research on both toxic and non-toxic anti-cancer agents. Consequently, the scope on the journal will cover both conventional cytotoxic chemotherapy and hormonal or biological response modalities such as interleukins and immunotherapy. Submitted articles undergo a preliminary review by the editor. Some articles may be returned to authors without further consideration. Those being considered for publication will undergo further assessment and peer-review by the editors and those invited to do so from a reviewer pool.